Johnson & Johnson (JNJ) 107.99 $JNJ
Final Glance: Pharmaceuticals companies
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Mr. David Guerette Joins Matamec's Board of Directors
Marketwire - Fri Sep 19, 2:01PM CDT
Matamec Explorations Inc. ("Matamec" or the "Company"
(TSX VENTURE: MAT)(OTCQX: MHREF) is pleased to announce that Mr. David Guerette has joined the Board of Directors at the Annual Meeting of the Shareholders of the Company held on last June 19.
Midday Glance: Pharmaceuticals companies
AP - Fri Sep 19, 12:33PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri Sep 19, 12:33PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Dividend Aristocrats: Time to Buy AbbVie Inc Stock?
George Budwell, The Motley Fool - Motley Fool - Fri Sep 19, 11:32AM CDT
Dividend stocks are a powerful force within a well-balanced portfolio because they can dramatically increase the rate of compounding interest through dividend reinvestment plans. Not all dividend stocks are great investment vehicles, however. For...
Gilead's Zydelig Approved In EU; Imbruvica In Wings
at Investor's Business Daily - Fri Sep 19, 11:17AM CDT
The European Commission (EC) approved Gilead Sciences' (GILD) drug Zydelig for two blood cancers on Friday, sending Gilead stock up as much as 1.9%, though shares were flat in midday trading in the stock market today. The EC approved the drug for...
Early Glance: Pharmaceuticals companies
AP - Fri Sep 19, 9:16AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Fri Sep 19, 9:16AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Stock Market News for September 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 9:10AM CDT
Benchmarks settled in the green on Thursday a day after Fed’s pledge to keep short-term interest rates near zero for a “considerable time”
Johnson & Johnson (JNJ) Approaches New Upside Target of $108.31
Comtex SmarTrend(R) - Fri Sep 19, 8:59AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $106.93 today and have reached the first resistance level of $107.83. Analysts will be watching for a cross of the next upside pivot targets of $108.31 and $109.69.
3 Best Stocks to Invest in Pharma
Dan Carroll, The Motley Fool - Motley Fool - Fri Sep 19, 8:13AM CDT
Big pharma's full of top stocks, with high-yielding dividends and pipelines brimming with promising drug candidates for the future. But which stocks in this industry are worth your money? The patent cliff has taken a hammer to many of the biggest...
Gilead Sciences, inc. Stock's Incoming Game Changer
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 18, 7:45AM CDT
Gilead Sciences ' Sovaldi may have revolutionized hepatitis C treatment, but it also served as a lightning rod of controversy over drugmakers' pricing of next-generation medicines. Sovaldi's ability to clear the virus in 90% of patients over 12...
First Bellwether Trial in the DePuy Orthopaedics Pinnacle Hip Device Litigation Continues in its Third Week, Parker Waichman LLP Comments
PRWeb - Wed Sep 17, 5:01PM CDT
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective medical devices, notes that the first bellwether trial involving Johnson & Johnson's DePuy Orthopaedics Pinnacle hip device is entering its third week and DePuy executives have been called to testify. The case is Herlihy-Paoli v. DePuy Orthopaedics Inc., U.S. District Court, Northern District of Texas (Dallas) (Case No.: 11-cv-3590).
Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org
PRWeb - Wed Sep 17, 9:31AM CDT
"North America Gynecological Devices Market Outlook to 2020″, provides key market data on the North America Gynecological Devices market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices (Tubal Clips and Rings)) Endometrial Ablation Devices (Thermal Balloon, Hydrothermal Ablation (HTA), Bipolar Energy, Cryotherapy and Microwave Endometrial Ablation Devices) Uterine Fibroid Embolization Agents (Poly Vinyl Alcohol Particles, Trisacryl Gelatin Microspheres and Gelatin Sponge) The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Gynecological Devices market wherever available. Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=10486 . The data in the report is derived from dynamic market forecast models. Epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases). Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis. Complete Report Details Available @ http://www.marketoptimizer.org/north-america-...-2020.html . Overview of Key Companies in North America Gynecological Devices Market: Conceptus, Inc. Hologic, Inc. Boston Scientific Corporation Cook Group Incorporated CooperSurgical, Inc. Merit Medical Systems, Inc. Utah Medical Products, Inc. Johnson & Johnson BSD Medical Corporation Scope Market size data for Gynecological Devices market segments - Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices (Tubal Clips and Rings)), Endometrial Ablation Devices (Thermal Balloon, Hydrothermal Ablation (HTA), Bipolar Energy, Cryotherapy and Microwave Endometrial Ablation Devices) and Uterine Fibroid Embolization Agents (Poly Vinyl Alcohol Particles, Trisacryl Gelatin Microspheres and Gelatin Sponge). Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020. 2013 company shares and distribution shares data for Gynecological Devices market. Global corporate-level profiles of key companies operating within the Gynecological Devices market. Key players covered include Bayer Healthcare, Hologic, Boston Scientific, Microsulis Medical Limited, Cook Medical and Merit Medical. Reasons to buy Develop business strategies by identifying the key market categories and segments poised for strong growth in the future. Develop market-entry and market expansion strategies. Design competition strategies by identifying who-stands-where in the market. Develop investment strategies by identifying the key market segments expected to register strong growth in the near future. What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize. Inquire before Buying @ http://www.marketoptimizer.org/contacts/inqui...name=10486 . (This is a premium report priced at US$3000 for a single user License.)
Final Glance: Pharmaceuticals companies
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Mr. David Guerette Joins Matamec's Board of Directors
Marketwire - Fri Sep 19, 2:01PM CDT
Matamec Explorations Inc. ("Matamec" or the "Company"
(TSX VENTURE: MAT)(OTCQX: MHREF) is pleased to announce that Mr. David Guerette has joined the Board of Directors at the Annual Meeting of the Shareholders of the Company held on last June 19. Midday Glance: Pharmaceuticals companies
AP - Fri Sep 19, 12:33PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri Sep 19, 12:33PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Dividend Aristocrats: Time to Buy AbbVie Inc Stock?
George Budwell, The Motley Fool - Motley Fool - Fri Sep 19, 11:32AM CDT
Dividend stocks are a powerful force within a well-balanced portfolio because they can dramatically increase the rate of compounding interest through dividend reinvestment plans. Not all dividend stocks are great investment vehicles, however. For...
Gilead's Zydelig Approved In EU; Imbruvica In Wings
at Investor's Business Daily - Fri Sep 19, 11:17AM CDT
The European Commission (EC) approved Gilead Sciences' (GILD) drug Zydelig for two blood cancers on Friday, sending Gilead stock up as much as 1.9%, though shares were flat in midday trading in the stock market today. The EC approved the drug for...
Early Glance: Pharmaceuticals companies
AP - Fri Sep 19, 9:16AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Fri Sep 19, 9:16AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Stock Market News for September 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 9:10AM CDT
Benchmarks settled in the green on Thursday a day after Fed’s pledge to keep short-term interest rates near zero for a “considerable time”
Johnson & Johnson (JNJ) Approaches New Upside Target of $108.31
Comtex SmarTrend(R) - Fri Sep 19, 8:59AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $106.93 today and have reached the first resistance level of $107.83. Analysts will be watching for a cross of the next upside pivot targets of $108.31 and $109.69.
3 Best Stocks to Invest in Pharma
Dan Carroll, The Motley Fool - Motley Fool - Fri Sep 19, 8:13AM CDT
Big pharma's full of top stocks, with high-yielding dividends and pipelines brimming with promising drug candidates for the future. But which stocks in this industry are worth your money? The patent cliff has taken a hammer to many of the biggest...
Gilead Sciences, inc. Stock's Incoming Game Changer
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 18, 7:45AM CDT
Gilead Sciences ' Sovaldi may have revolutionized hepatitis C treatment, but it also served as a lightning rod of controversy over drugmakers' pricing of next-generation medicines. Sovaldi's ability to clear the virus in 90% of patients over 12...
First Bellwether Trial in the DePuy Orthopaedics Pinnacle Hip Device Litigation Continues in its Third Week, Parker Waichman LLP Comments
PRWeb - Wed Sep 17, 5:01PM CDT
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective medical devices, notes that the first bellwether trial involving Johnson & Johnson's DePuy Orthopaedics Pinnacle hip device is entering its third week and DePuy executives have been called to testify. The case is Herlihy-Paoli v. DePuy Orthopaedics Inc., U.S. District Court, Northern District of Texas (Dallas) (Case No.: 11-cv-3590).
Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org
PRWeb - Wed Sep 17, 9:31AM CDT
"North America Gynecological Devices Market Outlook to 2020″, provides key market data on the North America Gynecological Devices market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices (Tubal Clips and Rings)) Endometrial Ablation Devices (Thermal Balloon, Hydrothermal Ablation (HTA), Bipolar Energy, Cryotherapy and Microwave Endometrial Ablation Devices) Uterine Fibroid Embolization Agents (Poly Vinyl Alcohol Particles, Trisacryl Gelatin Microspheres and Gelatin Sponge) The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Gynecological Devices market wherever available. Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=10486 . The data in the report is derived from dynamic market forecast models. Epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases). Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis. Complete Report Details Available @ http://www.marketoptimizer.org/north-america-...-2020.html . Overview of Key Companies in North America Gynecological Devices Market: Conceptus, Inc. Hologic, Inc. Boston Scientific Corporation Cook Group Incorporated CooperSurgical, Inc. Merit Medical Systems, Inc. Utah Medical Products, Inc. Johnson & Johnson BSD Medical Corporation Scope Market size data for Gynecological Devices market segments - Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices (Tubal Clips and Rings)), Endometrial Ablation Devices (Thermal Balloon, Hydrothermal Ablation (HTA), Bipolar Energy, Cryotherapy and Microwave Endometrial Ablation Devices) and Uterine Fibroid Embolization Agents (Poly Vinyl Alcohol Particles, Trisacryl Gelatin Microspheres and Gelatin Sponge). Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020. 2013 company shares and distribution shares data for Gynecological Devices market. Global corporate-level profiles of key companies operating within the Gynecological Devices market. Key players covered include Bayer Healthcare, Hologic, Boston Scientific, Microsulis Medical Limited, Cook Medical and Merit Medical. Reasons to buy Develop business strategies by identifying the key market categories and segments poised for strong growth in the future. Develop market-entry and market expansion strategies. Design competition strategies by identifying who-stands-where in the market. Develop investment strategies by identifying the key market segments expected to register strong growth in the near future. What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize. Inquire before Buying @ http://www.marketoptimizer.org/contacts/inqui...name=10486 . (This is a premium report priced at US$3000 for a single user License.)
